6/14
01:16 am
tenx
Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/14
08:15 am
tenx
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Low
Report
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
5/14
08:00 am
tenx
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Low
Report
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
4/30
07:42 am
tenx
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]
Low
Report
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]
4/30
07:30 am
tenx
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Low
Report
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
4/9
08:37 am
tenx
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” [Yahoo! Finance]
Medium
Report
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” [Yahoo! Finance]
4/9
08:30 am
tenx
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Low
Report
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
3/28
08:40 am
tenx
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results [Yahoo! Finance]
3/28
08:30 am
tenx
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
Medium
Report
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results